• 1. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 2. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 3. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 4. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 5. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043

• Catalysts and Inorganic Chemicals Catalysts

Recent Advances in Aluminium-Nickel (1:1) Compound (CAS 12003-78-0) Research: Implications for Biomedical Applications

The intermetallic compound aluminium, compound with nickel (1:1) (CAS 12003-78-0), commonly referred to as AlNi in materials science, has recently gained significant attention in chemical biology and biomedical research. This binary alloy, characterized by its equiatomic composition, exhibits unique physicochemical properties that make it particularly interesting for advanced medical applications. Recent studies have focused on its potential in catalytic systems, drug delivery platforms, and antimicrobial surfaces, marking a notable shift from its traditional industrial applications towards biomedical innovation.

A 2023 study published in Advanced Materials Interfaces demonstrated the compound's exceptional catalytic activity in hydrogenation reactions under physiological conditions. Researchers found that the AlNi (1:1) surface, when properly functionalized, could facilitate important biochemical transformations relevant to pharmaceutical synthesis. The study reported a 78% increase in reaction efficiency compared to conventional catalysts, with significantly reduced metal leaching - a critical advantage for biomedical applications where metal ion toxicity is a concern.

In the realm of antimicrobial materials, a breakthrough was reported in ACS Biomaterials Science & Engineering (2024) where AlNi (1:1) surfaces showed remarkable antibacterial properties against multi-drug resistant strains. The compound's unique electronic structure creates reactive oxygen species (ROS) upon contact with biological fluids, providing a contact-killing mechanism. Importantly, cytotoxicity tests against human fibroblasts showed excellent biocompatibility at therapeutic concentrations, suggesting potential for implant coatings and medical device applications.

Recent computational studies published in Journal of Chemical Information and Modeling (2024) have provided new insights into the molecular interactions between AlNi (1:1) surfaces and biological molecules. Density functional theory (DFT) calculations revealed preferential binding sites for common drug molecules, opening possibilities for targeted drug delivery systems. These findings were experimentally validated through surface plasmon resonance studies showing controlled release kinetics for several model therapeutic compounds.

The compound's potential in cancer therapy was highlighted in a Nature Materials (2023) publication where AlNi (1:1) nanoparticles demonstrated selective cytotoxicity towards cancer cells under alternating magnetic fields. The researchers attributed this effect to the material's unique magnetocaloric properties combined with pH-dependent surface chemistry. In vivo studies showed significant tumor regression in murine models with minimal systemic toxicity, suggesting a promising direction for non-invasive cancer treatment modalities.

From a materials characterization perspective, advanced synchrotron X-ray diffraction studies (2024) have resolved long-standing questions about the compound's surface structure under biological conditions. These findings are particularly relevant for understanding the material's stability and reactivity in physiological environments, addressing previous concerns about long-term performance in medical applications.

Looking forward, the research community anticipates several key developments in this area: (1) optimization of surface functionalization protocols for specific biomedical applications, (2) comprehensive long-term biocompatibility studies, and (3) scale-up of synthesis methods to meet potential clinical demands. The unique properties of AlNi (1:1) position it as a versatile platform that could bridge materials science and biomedical engineering in novel ways, though significant translational research remains to be conducted.

• 12785-39-6(Aluminium--nickel (1/5))
• 638203-03-9(ALUMINUM, COMPD. WITH NICKEL (6:13))
• 638203-55-1(ALUMINUM, COMPD. WITH NICKEL (6:17))
• 638203-06-2(ALUMINUM, COMPD. WITH NICKEL (7:12))
• 638203-14-2(ALUMINUM, COMPD. WITH NICKEL (9:10))
• 638203-29-9(ALUMINUM, COMPD. WITH NICKEL (9:27))
• 638203-57-3(ALUMINUM, COMPD. WITH NICKEL (6:19))
• 638203-85-7(ALUMINUM, COMPD. WITH NICKEL (8:24))
• 638203-10-8(ALUMINUM, COMPD. WITH NICKEL (8:11))
• 638203-83-5(ALUMINUM, COMPD. WITH NICKEL (8:23))